Merck & Co To Break New Ground With Female-Led Organon Unit
Former Chair And CEO Of Humacyte, Carrie Cox To Serve As Chair
The planned spin-off of Merck & Co’s Organon unit, with annual sales of $6.5bn including from biosimilars, is nearing completion, with the originator filing documentation with the SEC and unveiling a progressive female-majority board of directors for the new company.
You may also be interested in...
The Finnish company’s endometriosis candidate could offer a better safety profile and be the first drug to address disease progression, Organon claims. Q3 revenues declined slightly due to pandemic, generic competition.
With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.
In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.